���沙莫瑞林历史与监管定位 — Field Notes

By Editorial Desk · published 2026-04-13 · last reviewed 2026-05-04 · Topic

The short version of 稳定性 fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-05-04 and is reviewed periodically as new material appears.

特沙莫瑞林历史与监管定位

在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。

特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。

监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。

Analytical Methods and Storage Handling

Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.

Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.

Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.

Tesamorelin at a glance

Background and Clinical Development

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Related pages on this site

• Scheduled comparison
• Focused trends
• Lightweight collection
• Material trends
• Quality update
• Connected casebook
• Sustainable trends
• Quality playbook

Mechanism And Measurement Approaches

Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.

Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.

Background And Regulatory Development

Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.

Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.

检测方法、储存与处理

冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。

研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。

纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。

Background from the literature

== Clinical evidence == In a six-month randomized trial published in The New England Journal of Medicine in 2019, 168 people with type 1 diabetes were assigned either Control-IQ with a t:slim X2 and Dexcom G6 or a sensor-augmented pump. Mean time with glucose in the target range of 70–180 mg/dL rose from 61% to 71% in the Control-IQ group and remained about 59% in the control group, an adjusted difference of 11 percentage points, or 2.6 hours per day. No severe hypoglycemic events occurred; one participant using the closed-loop system developed diabetic ketoacidosis after an infusion-set failure. The trial was funded by the National Institute of Diabetes and Digestive and Kidney Diseases; Tandem supplied systems and technical support but, according to the publication, did not control the study design, conduct or analysis. A 13-week randomized trial published in the same journal in 2025 enrolled 319 adults with insulin-treated type 2 diabetes. Time in the target range increased from 48% to 64% with Control-IQ, compared with 51% to 52% in a control group that continued its previous insulin method; the adjusted difference was 14 percentage points. Glycated hemoglobin fell by 0.9 percentage points in the automated-delivery group and by 0.4 points in the control group. One severe hypoglycemic event occurred in the automated-delivery group. The study was funded by Tandem.

== Biosynthesis == A novel aspect of PQQ is its biosynthesis in bacteria from a ribosomally translated precursor peptide, PqqA. A glutamic acid and a tyrosine in PqqA are cross-linked by the radical SAM enzyme PqqE with the help of PqqD in the first step of PqqA modification. A protease then liberates the Glu-Tyr molecule from the peptide backbone. PqqB oxidizes the 2 and 3 positions on the tyrosine ring, forming a quinone which quickly becomes AHQQ, finishing the pyridine ring. PqqC then forms the final pyrrole ring.

== Animal studies and PhIP == Rats were fed PhIP at concentrations of 25, 100, and 200 ppm. The rats gained weight throughout the experiment, but feeding concentration of PhIP remained constant. Rats were fed PhIP ad libitum at concentrations of 12.5 and 50ppm. Rats developed mammary tumors at each concentration of PhIP administered. An in vivo study found mice injected with 5, 10, 12, 18, 20, 24, 28, 32, or 36 mg/kg bw showed a strong correlation between consumption of PhIP and genetic damage.

Sequence variation of Bemisia tabaci Chemosensory protein 2 in cryptic species B and Q: new DNA markers for whitefly recognition. Gene 2016a; 576: 284-291. 26. Zhu J, Wang G, Pelosi P. Plant transcriptomes reveal hidden guests. Biochem Biophys Res Commun. 2016; 474: 497-502. 27. Perkin LC, Friesen KS, Flinn PW, Oppert B. Venom gland components of the ectoparasitoid wasp, Anisopteromalus calandrae. J. Venom Res. 2015; 6: 19-37. 28. Celorio-Mancera MdP, Sundmalm SM, Vogel H, Rutishauser D, Ytterberg AJ, Zubarv RA et al. Chemosensory proteins, major salivary factors in caterpillar mandibular glands. Insect Biochem Mol Biol. 2012; 42: 796-805. 29. González-Caballero N, Valenzuela JG, Ribeiro JMC, Cuervo P, Brazil RP. Transcriptome exploration of the sex pheromone gland of Lutzomyia longipalpis (Diptera: Psychodidae: Phlebotominae). Parasit Vect. 2013; 6: 56. 30. Liu YL, Guo H, Huang LQ, Pelosi P, Wang CZ. Unique function of a chemosensory protein in the proboscis of two Helicoverpa species. J Exp Biol. 2014; 217: 1821-1826. 31. Zhu J, Iovinella I, Dani FR, Liu YL, Huang LQ, Liu Y, et al. Conserved chemosensory proteins in the proboscis and eyes of Lepidoptera. Int J Biol Sci. 2016; 12: 1394-1404. 32. Xuan N, Guo X, Xie HY, Lou QN, Bo LX, Liu GX, et al. Increased expression of CSP and CYP genes in adult silkworm females exposed to avermectins. Insect Sci. 2015; 22: 203-219. 33. Sabatier L, Jouanguy E, Dostert C, Zachary D, Dimarcq JL, Bulet P, et al.

Dunnigan-type familial partial lipodystrophy, also known as FPLD Type II and abbreviated as (FPLD2), is a rare monogenic form of insulin resistance characterized by loss of subcutaneous fat from the extremities, trunk, and gluteal region. FPLD recapitulates the main metabolic attributes of the insulin resistance syndrome, including central obesity, hyperinsulinemia, glucose intolerance and diabetes usually type 2, dyslipidemia, hypertension, and early endpoints of atherosclerosis. It can also result in hepatic steatosis. FPLD results from mutations in LMNA gene, which is the gene that encodes nuclear lamins A and C. The condition is named after Scottish doctor Matthew Dunnigan, who pioneered early study into the disorder.

Sources: en.wikipedia.org

Further detail

=== 1988 to 2011: Reduced again but back on operations === At the end of the Cold War, the TA had a strength of 72,823, including 3,297 in the Home Service Force (HSF). in the 1991 Gulf War 205 Scottish General Hospital was mobilised as a unit based in Riyadh, Saudi Arabia, and a number of TA staff officers and others volunteered and served during the conflict, either in supporting roles in Germany or within 1 (UK) Armoured Division in the Middle East. In December 1991, as part of the reductions in Options for Change, it was announced that the TA's establishment was to be reduced to 63,000, while the HSF element was to be disbanded. In July 1994, this was further reduced to 59,000. The Reserve Forces Act of May 1996 was a landmark reform, making it much easier to call out any element of the Reserves at the behest of the Secretary of State for a range of purposes including 'protection of life or property' well short of the criteria for Queen's Order (e.g. 'great emergency', 'imminent national danger'). It also provides protection in employment law for members' civilian jobs should they be mobilised. This has led to the Army Reserve increasingly providing routine support for the Regular Army overseas including the delivery of composite units to release regular units from standing liabilities; including Bosnia, Kosovo, Cyprus and the Falkland Islands. Some 2,800 TA personnel volunteered for and deployed on Operation Resolute from 1995 to 1998, the UK's contribution to the NATO mission to enforce peace in the Former Yugoslavia.

=== Toxicity === Just as selenomethionine can be randomly incorporated into proteins, selenocystine can also be mistakenly attached to tRNACys by cysteinyl-tRNA synthetase and incorporated into proteins in lieu of cystine. This causes considerable toxicity. A variant synthase that can distinguish between Cys and Sec helps reduce toxicity.

== Regulatory aspects == A transdermal patch is classified by the U.S. Food and Drug Administration as a combination product, consisting of a medical device combined with a drug or biological product that the device is designed to deliver. Prior to sale in the United States, any transdermal patch product must apply for and receive approval from the Food and Drug Administration, demonstrating safety and efficacy for its intended use.

Helen Jill Cooper is a British chemist who is Professor of mass spectrometry at the University of Birmingham. She serves as Deputy Head of the School of Chemistry and holds an Engineering and Physical Sciences Research Council Established Career Fellowship. Her research considers the development of native ambient mass spectrometry to enable direct analysis of intact proteins and protein assemblies from tissue.

Sources: en.wikipedia.org

Frequently asked questions